ADVFN Logo ADVFN
市場データ
ニュース
投資ツール
市場
発見

Hot Features

Follow Feed

フォローフィードコミュニティでトレーダーや投資家とつながりましょう.

ライブオプションフロー

包括的なオプション データを調査し、オプション フローで高度なフィルターを使用します.

モニター

ターミナル モニターで株式と資産のウォッチリストを整理および監視します
サインイン Premium Iconプレミアム Help Menu
Bitcoin
67,989.95
0.60%
S&P 500
5,266.95
-0.74%
Dow Jones
38,441.54
-1.06%
US Dollar vs Yen
157.335
-0.18%
Brent Oil
83.385
0.01%
Registration Strip Icon for charts 登録してリアルタイムのチャート、分析ツール、価格を入手してください。
登録
  1. ホーム
  2. 投資
  3. 株式
  4. アメリカ
  5. NASDAQ
  6. Sensei Biotherapeutics Inc (SNSE)

  7. Sensei Biotherapeutics Inc (SNSE) ニュース

SNSE

Sensei Biotherapeutics (SNSE)

Sensei Biotherapeutics Inc
から:
次の項目別のソート:
 Showing the most relevant articles for your search:NASDAQ:SNSE
日付受信時刻ニュースソース見出しコード企業名
2024/05/2406 : 10Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SNSESensei Biotherapeutics Inc
2024/05/1005 : 31Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:SNSESensei Biotherapeutics Inc
2024/05/0920 : 37Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SNSESensei Biotherapeutics Inc
2024/03/0606 : 44Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SNSESensei Biotherapeutics Inc
2024/02/2821 : 31Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SNSESensei Biotherapeutics Inc
2024/02/1708 : 37Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SNSESensei Biotherapeutics Inc
2024/02/1708 : 28Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SNSESensei Biotherapeutics Inc
2024/02/1708 : 25Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SNSESensei Biotherapeutics Inc
2024/02/0906 : 31Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SNSESensei Biotherapeutics Inc
2024/01/0422 : 14Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SNSESensei Biotherapeutics Inc
2023/11/0806 : 40Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:SNSESensei Biotherapeutics Inc
2023/11/0721 : 35Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SNSESensei Biotherapeutics Inc
2023/11/0721 : 30GlobeNewswire Inc.Sensei Biotherapeutics Reports Third Quarter 2023 Financial Results and Recent Business HighlightsNASDAQ:SNSESensei Biotherapeutics Inc
2023/11/0620 : 07Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SNSESensei Biotherapeutics Inc
2023/11/0405 : 11Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SNSESensei Biotherapeutics Inc
2023/11/0405 : 05GlobeNewswire Inc.Sensei Biotherapeutics Reports Favorable Clinical Data for SNS-101 at 2023 SITC Annual MeetingNASDAQ:SNSESensei Biotherapeutics Inc
2023/11/0305 : 53Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SNSESensei Biotherapeutics Inc
2023/11/0305 : 50Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:SNSESensei Biotherapeutics Inc
2023/11/0120 : 30GlobeNewswire Inc.Sensei Biotherapeutics Appoints Stephanie Krebs, MS, MBA, as Chief Business OfficerNASDAQ:SNSESensei Biotherapeutics Inc
2023/10/2522 : 05GlobeNewswire Inc.Sensei Biotherapeutics to Present Initial Clinical Data from Dose Escalation Trial of SNS-101 at 2023 SITC Annual MeetingNASDAQ:SNSESensei Biotherapeutics Inc
2023/10/2320 : 30GlobeNewswire Inc.Sensei Biotherapeutics Presents Trial-in-Progress Poster for Phase 1/2 Clinical Study of SNS-101 at ESMO 2023NASDAQ:SNSESensei Biotherapeutics Inc
2023/10/2106 : 01Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SNSESensei Biotherapeutics Inc
2023/09/2720 : 30GlobeNewswire Inc.Sensei Biotherapeutics Announces Initiation of Combination Arm for Phase 1/2 Clinical Study of SNS-101 with Regeneron’s Libtayo®NASDAQ:SNSESensei Biotherapeutics Inc
2023/09/2120 : 30GlobeNewswire Inc.Sensei Biotherapeutics Presents New Preclinical Data Reinforcing SNS-101 Pharmacokinetic Profile, Safety Characteristics and Mechanism of Action at the Seventh CRI-ENCI-AACR International Cancer Immunotherapy ConferenceNASDAQ:SNSESensei Biotherapeutics Inc
2023/09/1321 : 43Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SNSESensei Biotherapeutics Inc
2023/09/1320 : 30GlobeNewswire Inc.Sensei Biotherapeutics to Present New Preclinical Data Supporting Mechanism of Action, Pharmacokinetic Profile and Safety Characteristics for SNS-101, a Conditionally Active VISTA-blocking Antibody, at the Seventh CRI-ENCI-AACR International Cancer ImmunotNASDAQ:SNSESensei Biotherapeutics Inc
2023/09/1206 : 34Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SNSESensei Biotherapeutics Inc
2023/09/1206 : 33Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SNSESensei Biotherapeutics Inc
2023/09/1206 : 33Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SNSESensei Biotherapeutics Inc
2023/09/1206 : 31Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SNSESensei Biotherapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:SNSE

最近閲覧した銘柄

BIT
UB5939
Unicredit Bank
BOV
USIMS135
USIMS135 Ex:13,22
BIT
F38918
Vontobel Financial Produ...
BIT
P1MNF8
BNP Paribas Issuance
BIT
F15045
Vontobel Financial Produ...
AMEX
BSR
Beacon Selective Risk ETF
BIT
F39134
Vontobel Financial Produ...
BIT
F21518
Vontobel Financial Produ...
BIT
P1LVR8
BNP Paribas Issuance
BIT
F33692
Vontobel Financial Produ...
COIN
TALUSD
BIT
P39802
Bnp Paribas Issuance
DGFX
EAIUSDT
EDAIN
BOV
E1QN34
Equinor ASA
BIT
P1TCK6
BNP Paribas Issuance
BIT
F39308
Vontobel Financial Produ...
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

日本
会社情報
ビジネス
人気
アプリを入手
App Store
Google Play

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約

© 2024 ADVFN PLC - 全著作権所有